HDAC inhibitors, including belinostat, romidepsin, panobinostat, entinostat, and vorinostat, have emerged as important therapeutic agents in the treatment of leukemia and lymphoma by targeting various classes of HDACs. Here, HDAC9 is linked to leukemia.